p53 Immunoreactivity in inflammatory and neoplastic diseases of the uterine cervix
- 1 April 1993
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 169 (4) , 425-430
- https://doi.org/10.1002/path.1711690407
Abstract
Immunoreactivity for the tumour suppressor gene product p53 is commonly found in many different human malignancies and few premalignant lesions. Data on cervical neoplasms, however, are still lacking. We retrospectively investigated p53 immunoreactivity in 92 lesions of the uterine cervix, including 44 cases of chronic cervicitis, 29 squamous intraepithelial lesions (SILs), and 19 invasive carcinomas. p53 immunoreactivity confined to the basal cell layer, was detected in 74 per cent of cases showing chronic cervicitis and in all cases with low-grade SILs. Conversely, suprabasal and/or diffuse p53 immunoreactivity was exclusively demonstrated in 25 per cent of high-grade SILs and in 74 per cent of invasive carcinomas. The results of this investigation document a high prevalence of p53-immunoreactive malignant tumours of the uterine cervix. In high-grade SILs, p53-immunoreactive cells paralleled the height of involvement by dysplastic changes within the squamous epithelium. A prolonged half-life of the protein is the most likely explanation for the occurrence of p53 immunoreactivity in neoplastic cells. The unexpected finding of p53-immunoreactive cells in inflammatory lesions, though possibly related to an increased proliferation rate of the basal cell compartment, requires further study and underlines the need for a careful approach to p53 immunocytochemistry.Keywords
This publication has 13 references indexed in Scilit:
- Abnormal p53 Expression in Lung Neuroendocrine Tumors Diagnostic and Prognostic ImplicationsDiagnostic Molecular Pathology, 1992
- Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumoursThe Lancet, 1992
- Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasmsThe Journal of Pathology, 1992
- P53 in tumour pathology: Can we trust immunocytochemistry?The Journal of Pathology, 1992
- P53 protein expression in lymphomas and reactive lymphoid tissueThe Journal of Pathology, 1992
- p53 and Human MalignanciesAdvances in Cancer Research, 1991
- p53 mutations in colorectal cancer.Proceedings of the National Academy of Sciences, 1990
- Increased expression of mutant forms of p53 oncogene in primary lung cancerThe Lancet, 1990
- p53: oncogene or anti-oncogene?Genes & Development, 1990
- The 1988 Bethesda System for Reporting Cervical/Vaginal Cytological DiagnosesJAMA, 1989